Density of CD3+ and CD8+ cells in gingivo-buccal oral squamous cell carcinoma is associated with lymph node metastases and survival.
Adult
Aged
Aged, 80 and over
CD3 Complex
/ metabolism
CD8 Antigens
/ metabolism
Carcinoma, Squamous Cell
/ immunology
Disease Progression
Female
Humans
Lymph Node Excision
Lymphatic Metastasis
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Margins of Excision
Middle Aged
Mouth Neoplasms
/ immunology
Neoplasm Staging
Prognosis
Survival Analysis
Tumor Microenvironment
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
06
2020
accepted:
27
10
2020
entrez:
19
11
2020
pubmed:
20
11
2020
medline:
9
1
2021
Statut:
epublish
Résumé
The tumor immune microenvironment is emerging as a critical player in predicting cancer prognosis and response to therapies. However, the prognostic value of tumor-infiltrating immune cells in Gingivo-Buccal Oral Squamous Cell Carcinoma (GBOSCC) and their association with tumor size or lymph node metastases status require further elucidation. To study the relationship of tumor-infiltrating immune cells with tumor size (T stage) and lymph node metastases (N stages), we analyzed the density of tumor-infiltrating immune cells in archived, whole tumor resections from 94 patients. We characterized these sections by immune-histochemistry using 12 markers and enumerated tumor-infiltrating immune cells at the invasive margins (IM) and centers of tumors (CT). We observed that a higher density of CD3+ cells in the IM and CT was associated with smaller tumor size (T1-T2 stage). Fewer CD3+ cells was associated with larger tumor size (T3-T4 stage). High infiltration of CD3+and CD8+ cells in IM and CT as well as high CD4+ cell infiltrates in the IM was significantly associated with the absence of lymph node metastases. High infiltrates of CD3+ and CD8+ cells in CT was associated with significantly improved survival. Our results illustrate that the densities and spatial distribution of CD3+ and CD8+ cell infiltrates in primary GBOSCC tumors is predictive of disease progression and survival. Based on our findings, we recommend incorporating immune cell quantification in the TNM classification and routine histopathology reporting of GBOSCC. Immune cell quantification in CT and IM may help predict the efficacy of future therapies.
Identifiants
pubmed: 33211709
doi: 10.1371/journal.pone.0242058
pii: PONE-D-20-17762
pmc: PMC7676650
doi:
Substances chimiques
CD3 Complex
0
CD8 Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0242058Déclaration de conflit d'intérêts
NO authors have competing interests.
Références
Elife. 2018 Sep 04;7:
pubmed: 30179157
Indian J Otolaryngol Head Neck Surg. 2015 Mar;67(Suppl 1):98-104
pubmed: 25621262
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Cell. 2016 Mar 10;164(6):1233-1247
pubmed: 26967289
Curr Treat Options Oncol. 2017 Jul;18(7):40
pubmed: 28555375
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Curr Treat Options Oncol. 2017 May;18(5):32
pubmed: 28474265
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Lancet Oncol. 2019 Jul;20(7):891-892
pubmed: 31201138
Hum Immunol. 1999 Jul;60(7):591-7
pubmed: 10426276
J Oral Pathol Med. 2018 Apr;47(4):359-367
pubmed: 29469989
Cancer Immunol Immunother. 2020 Mar;69(3):465-476
pubmed: 31950224
Mod Pathol. 2018 Jun;31(6):910-922
pubmed: 29416107
Anticancer Res. 2015 Jan;35(1):311-7
pubmed: 25550565
Oral Oncol. 2009 Feb;45(2):135-40
pubmed: 18621571
BMC Cancer. 2018 Mar 27;18(1):324
pubmed: 29580212
Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3
pubmed: 30537506
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
J Cancer Res Ther. 2009 Apr-Jun;5(2):71-7
pubmed: 19542661
Sci Transl Med. 2016 Feb 24;8(327):327ra26
pubmed: 26912905
Cancer Med. 2019 Jan;8(1):80-93
pubmed: 30600646
Sci Immunol. 2019 Oct 18;4(40):
pubmed: 31628161
Rep Pract Oncol Radiother. 2018 May-Jun;23(3):143-153
pubmed: 29760589
Immunol Rev. 2016 Sep;273(1):329-43
pubmed: 27558344
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
J Oral Pathol Med. 2019 Oct;48(9):788-798
pubmed: 31323145
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Adv Exp Med Biol. 2017;1036:19-31
pubmed: 29275462
Lancet Oncol. 2018 Dec;19(12):e664
pubmed: 30507424
Mol Cancer. 2019 Mar 30;18(1):63
pubmed: 30927923
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
Br J Cancer. 2019 Apr;120(7):714-727
pubmed: 30808992
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Adv Anat Pathol. 2017 Sep;24(5):235-251
pubmed: 28777142
Oral Oncol. 2013 Sep;49(9):872-877
pubmed: 23830839
Oral Oncol. 2015 Jan;51(1):90-5
pubmed: 25283344
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
J Immunol. 2019 Jan 1;202(1):278-291
pubmed: 30530592
Cancer Res. 2009 Mar 15;69(6):2685-93
pubmed: 19258510
Clin Cancer Res. 2006 Jan 15;12(2):465-72
pubmed: 16428488
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
J Cancer. 2013;4(1):66-83
pubmed: 23386906
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Ear Nose Throat J. 2019 Aug;98(7):E112-E119
pubmed: 31072197
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Int J Cancer. 2019 Nov 1;145(9):2568-2579
pubmed: 30924133
Front Immunol. 2019 Aug 20;10:1875
pubmed: 31481956
Sci Rep. 2019 Sep 16;9(1):13341
pubmed: 31527658
Ann Oncol. 2017 Dec 1;28(suppl_12):xii18-xii32
pubmed: 29045511
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
J Cell Biochem. 2007 Jul 1;101(4):805-15
pubmed: 17226777
Head Neck Oncol. 2010 Mar 12;2:6
pubmed: 20226055
Clin Oral Investig. 2020 Feb;24(2):747-755
pubmed: 31139977
Head Neck Pathol. 2014 Mar;8(1):77-87
pubmed: 24002971
Semin Oncol. 2014 Apr;41(2):217-34
pubmed: 24787294
J Natl Compr Canc Netw. 2015 Jul;13(7):847-55; quiz 856
pubmed: 26150579
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Indian J Cancer. 2015 Oct-Dec;52(4):605-10
pubmed: 26960492
Proc Natl Acad Sci U S A. 2012 May 29;109(22):8358-9
pubmed: 22615400
Science. 2016 May 6;352(6286):658-60
pubmed: 27151852
Head Neck. 2005 Jul;27(7):597-602
pubmed: 15825204
Cell Rep. 2018 Apr 3;23(1):181-193.e7
pubmed: 29617659
BMC Cancer. 2019 Feb 4;19(1):120
pubmed: 30717704
Oral Oncol. 2010 Mar;46(3):185-9
pubmed: 20060355
Biomed Res Int. 2014;2014:838632
pubmed: 24883329
Cancer Discov. 2015 Mar;5(3):239-44
pubmed: 25643909
Br J Cancer. 2017 Aug 8;117(4):451-460
pubmed: 28704840
Int J Oral Maxillofac Surg. 2015 Jan;44(1):23-8
pubmed: 25457832
BMC Cancer. 2017 May 26;17(1):375
pubmed: 28549420
Hum Pathol. 2018 Dec;82:104-112
pubmed: 30036594